PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31550911-1	2020	NAP (NAPVSIPQ) is a small peptide derived from the activity-dependent neuroprotective protein (ADNP), which provides neuroprotection against amyloid-beta peptide toxicity associated with Alzheimer disease.	davunetide	0-3	activity dependent neuroprotector homeobox	Homo sapiens	51-93
31640849-0	2020	Neuroprotective Peptide NAPVSIPQ Antagonizes Ethanol Inhibition of L1 Adhesion by Promoting the Dissociation of L1 and Ankyrin-G.	davunetide	24-32	ankyrin 3, epithelial	Mus musculus	119-128
31640849-2	2020	This action of ethanol is antagonized by femtomolar concentrations of the neuropeptide NAPVSIPQ (NAP), an active fragment of the activity-dependent neuroprotective protein (ADNP).	davunetide	87-95	activity-dependent neuroprotective protein	Mus musculus	129-171
31640849-2	2020	This action of ethanol is antagonized by femtomolar concentrations of the neuropeptide NAPVSIPQ (NAP), an active fragment of the activity-dependent neuroprotective protein (ADNP).	davunetide	87-95	activity-dependent neuroprotective protein	Mus musculus	173-177
31640849-2	2020	This action of ethanol is antagonized by femtomolar concentrations of the neuropeptide NAPVSIPQ (NAP), an active fragment of the activity-dependent neuroprotective protein (ADNP).	davunetide	87-90	activity-dependent neuroprotective protein	Mus musculus	129-171
31640849-2	2020	This action of ethanol is antagonized by femtomolar concentrations of the neuropeptide NAPVSIPQ (NAP), an active fragment of the activity-dependent neuroprotective protein (ADNP).	davunetide	87-90	activity-dependent neuroprotective protein	Mus musculus	173-177
31640849-7	2020	RESULTS: Femtomolar concentrations of NAP stimulated the phosphorylation of tyrosine-1229 (L1-Y1229) at the ankyrin binding motif of the L1 cytoplasmic domain, leading to the dissociation of L1 from ankyrin-G and the spectrin-actin cytoskeleton.	davunetide	38-41	ankyrin 3, epithelial	Mus musculus	199-208
31640849-8	2020	NAP increased the association of L1 and EphB2 and directly activated EphB2 phosphorylation of L1-Y1229.	davunetide	0-3	Eph receptor B2	Mus musculus	40-45
31640849-8	2020	NAP increased the association of L1 and EphB2 and directly activated EphB2 phosphorylation of L1-Y1229.	davunetide	0-3	Eph receptor B2	Mus musculus	69-74
31640849-11	2020	CONCLUSIONS: NAP potently antagonizes ethanol inhibition of L1 adhesion by stimulating EphB2 phosphorylation of L1-Y1229.	davunetide	13-16	Eph receptor B2	Mus musculus	87-92
31640849-12	2020	EphB2 plays a critical role in synaptic development; its potent activation by NAP suggests that ADNP may mediate synaptic development partly by activating EphB2.	davunetide	78-81	Eph receptor B2	Mus musculus	0-5
31640849-12	2020	EphB2 plays a critical role in synaptic development; its potent activation by NAP suggests that ADNP may mediate synaptic development partly by activating EphB2.	davunetide	78-81	activity-dependent neuroprotective protein	Mus musculus	96-100
31640849-12	2020	EphB2 plays a critical role in synaptic development; its potent activation by NAP suggests that ADNP may mediate synaptic development partly by activating EphB2.	davunetide	78-81	Eph receptor B2	Mus musculus	155-160
31550911-1	2020	NAP (NAPVSIPQ) is a small peptide derived from the activity-dependent neuroprotective protein (ADNP), which provides neuroprotection against amyloid-beta peptide toxicity associated with Alzheimer disease.	davunetide	0-3	activity dependent neuroprotector homeobox	Homo sapiens	95-99
31550911-1	2020	NAP (NAPVSIPQ) is a small peptide derived from the activity-dependent neuroprotective protein (ADNP), which provides neuroprotection against amyloid-beta peptide toxicity associated with Alzheimer disease.	davunetide	5-13	activity dependent neuroprotector homeobox	Homo sapiens	51-93
31550911-1	2020	NAP (NAPVSIPQ) is a small peptide derived from the activity-dependent neuroprotective protein (ADNP), which provides neuroprotection against amyloid-beta peptide toxicity associated with Alzheimer disease.	davunetide	5-13	activity dependent neuroprotector homeobox	Homo sapiens	95-99
31992971-4	2019	Furthermore, novel peptide derivatives of the neuroprotective ADNP-snippet NAP (NAPVSIPQ), developed in our laboratory, include SKIP and the mirroring all D-amino acid SKIP (D-SKIP).	davunetide	80-88	activity-dependent neuroprotective protein	Mus musculus	62-66
31632241-1	2019	Activity-dependent neuroprotective protein (ADNP) has been initially discovered through its eight amino acid sequence NAPVSIPQ, which shares SIP motif with SALLRSIPA - a peptide derived from activity-dependent neurotrophic factor (ADNF).	davunetide	118-126	activity dependent neuroprotector homeobox	Homo sapiens	0-42
31632241-1	2019	Activity-dependent neuroprotective protein (ADNP) has been initially discovered through its eight amino acid sequence NAPVSIPQ, which shares SIP motif with SALLRSIPA - a peptide derived from activity-dependent neurotrophic factor (ADNF).	davunetide	118-126	activity dependent neuroprotector homeobox	Homo sapiens	44-48
30865715-0	2019	NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies.	davunetide	5-15	catenin beta like 1	Homo sapiens	0-3
30865715-7	2019	Clinically, NAP (davunetide, CP201) exhibited efficacy in prodromal Alzheimer"s disease patients (Tau3R/4R tauopathy) but not in progressive supranuclear palsy (increased Tau4R tauopathy).	davunetide	17-27	catenin beta like 1	Homo sapiens	12-15
30142893-9	2018	It is thus plausible that microtubule hyperacetylation promotes tumor progression by enhancing microtubule sensitivity to KL1, thereby disrupting spindle microtubules and this process could be reversed by the microtubule-binding and microtubule protective octapeptide NAPVSIPQ (NAP) which recruits tau to the microtubules.	davunetide	268-276	KIT ligand	Homo sapiens	122-125
30106381-4	2018	Mechanistically, ADNP includes a SIP motif embedded in the ADNP-derived snippet drug candidate NAP (NAPVSIPQ, also known as CP201), which binds to microtubule end-binding protein 3, essential for dendritic spine formation.	davunetide	100-108	activity dependent neuroprotector homeobox	Homo sapiens	17-21
30106381-4	2018	Mechanistically, ADNP includes a SIP motif embedded in the ADNP-derived snippet drug candidate NAP (NAPVSIPQ, also known as CP201), which binds to microtubule end-binding protein 3, essential for dendritic spine formation.	davunetide	100-108	activity dependent neuroprotector homeobox	Homo sapiens	59-63
30106381-4	2018	Mechanistically, ADNP includes a SIP motif embedded in the ADNP-derived snippet drug candidate NAP (NAPVSIPQ, also known as CP201), which binds to microtubule end-binding protein 3, essential for dendritic spine formation.	davunetide	100-108	microtubule associated protein RP/EB family member 3	Homo sapiens	159-180
28115743-2	2017	An eight-amino-acid peptide snippet of ADNP, NAP (NAPVSIPQ), identified as a smallest active fragment, includes the SxIP microtubule (MT) end-binding protein (EB) association motif, and enhances ADNP-EB3 interaction.	davunetide	50-58	activity dependent neuroprotector homeobox	Homo sapiens	39-43
28115743-2	2017	An eight-amino-acid peptide snippet of ADNP, NAP (NAPVSIPQ), identified as a smallest active fragment, includes the SxIP microtubule (MT) end-binding protein (EB) association motif, and enhances ADNP-EB3 interaction.	davunetide	50-58	activity dependent neuroprotector homeobox	Homo sapiens	195-199
28257938-3	2017	It is reported that davunetide, an octapeptide derived from activity-dependent neuroprotective protein (ADNP), inhibited Abeta aggregation and Abeta-induced neurotoxicity.	davunetide	20-30	activity-dependent neuroprotector homeobox	Rattus norvegicus	60-102
28257938-3	2017	It is reported that davunetide, an octapeptide derived from activity-dependent neuroprotective protein (ADNP), inhibited Abeta aggregation and Abeta-induced neurotoxicity.	davunetide	20-30	activity-dependent neuroprotector homeobox	Rattus norvegicus	104-108
28257938-3	2017	It is reported that davunetide, an octapeptide derived from activity-dependent neuroprotective protein (ADNP), inhibited Abeta aggregation and Abeta-induced neurotoxicity.	davunetide	20-30	amyloid beta precursor protein	Rattus norvegicus	121-126
28257938-7	2017	Western blotting experiments showed a significant decrease in the level of hippocampal p-AKT (Ser473), not total AKT, in Abeta1-42 only group, which was mostly antagonized by davunetide treatment.	davunetide	175-185	AKT serine/threonine kinase 1	Rattus norvegicus	89-92
28257938-8	2017	These findings demonstrate that davunetide, probably by enhancing PI3K/AKT pathway, plays an important positive role in attenuating Abeta1-42-induced impairments in spatial memory and synaptic plasticity, suggesting that davunetide could be an effective therapeutic candidate for the prevention and treatment of neurodegenerative disease such as AD.	davunetide	32-42	AKT serine/threonine kinase 1	Rattus norvegicus	71-74
28257938-8	2017	These findings demonstrate that davunetide, probably by enhancing PI3K/AKT pathway, plays an important positive role in attenuating Abeta1-42-induced impairments in spatial memory and synaptic plasticity, suggesting that davunetide could be an effective therapeutic candidate for the prevention and treatment of neurodegenerative disease such as AD.	davunetide	221-231	AKT serine/threonine kinase 1	Rattus norvegicus	71-74
25955282-4	2016	The ADNP-EB-binding SIP domain is shared with the ADNP snippet drug candidate, NAPVSIPQ termed NAP (davunetide).	davunetide	79-87	activity dependent neuroprotector homeobox	Homo sapiens	4-8
27870441-6	2017	NAP (davunetide), an ADNP snippet drug candidate, protects cognition in patients suffering from amnestic MCI preceding Alzheimer"s disease and significantly enhances functional daily activities in schizophrenia patients toward future development.	davunetide	5-15	activity dependent neuroprotector homeobox	Homo sapiens	21-25
26816081-1	2016	NAPVSIPQ (NAP) and all D-amino acid SALLRSIPA (D-SAL) are neuroprotective peptides derived from activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF), respectively.	davunetide	0-8	activity-dependent neuroprotector homeobox	Rattus norvegicus	96-138
26816081-1	2016	NAPVSIPQ (NAP) and all D-amino acid SALLRSIPA (D-SAL) are neuroprotective peptides derived from activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF), respectively.	davunetide	0-8	activity-dependent neuroprotector homeobox	Rattus norvegicus	140-144
25955282-4	2016	The ADNP-EB-binding SIP domain is shared with the ADNP snippet drug candidate, NAPVSIPQ termed NAP (davunetide).	davunetide	79-87	activity dependent neuroprotector homeobox	Homo sapiens	50-54
25955282-4	2016	The ADNP-EB-binding SIP domain is shared with the ADNP snippet drug candidate, NAPVSIPQ termed NAP (davunetide).	davunetide	100-110	activity dependent neuroprotector homeobox	Homo sapiens	4-8
25955282-4	2016	The ADNP-EB-binding SIP domain is shared with the ADNP snippet drug candidate, NAPVSIPQ termed NAP (davunetide).	davunetide	100-110	activity dependent neuroprotector homeobox	Homo sapiens	50-54
25955282-5	2016	Thus, we identified a precise target for ADNP/NAP (davunetide) neuroprotection toward improved drug development.	davunetide	51-61	activity dependent neuroprotector homeobox	Homo sapiens	41-45
26553741-3	2015	The NAP (NAPVSIPQ) sequence of activity-dependent neuroprotective protein (ADNP) contains the SxIP motif, microtubule end binding (EB) protein target, which is critical for microtubule dynamics leading to synaptic plasticity and neuroprotection.	davunetide	9-17	activity-dependent neuroprotective protein	Mus musculus	31-73
26553741-3	2015	The NAP (NAPVSIPQ) sequence of activity-dependent neuroprotective protein (ADNP) contains the SxIP motif, microtubule end binding (EB) protein target, which is critical for microtubule dynamics leading to synaptic plasticity and neuroprotection.	davunetide	9-17	activity-dependent neuroprotective protein	Mus musculus	75-79
25727410-0	2015	NAP (davunetide) protects primary hippocampus culture by modulating expression profile of antioxidant genes during limiting oxygen conditions.	davunetide	5-15	catenin, beta like 1	Rattus norvegicus	0-3
24873720-1	2014	BACKGROUND: In preclinical studies, davunetide promoted microtubule stability and reduced tau phosphorylation.	davunetide	36-46	microtubule associated protein tau	Homo sapiens	90-93
25505609-0	2014	Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing alpha-synuclein.	davunetide	16-26	synuclein, alpha	Mus musculus	130-145
24873720-2	2014	Because progressive supranuclear palsy (PSP) is linked to tau pathology, davunetide could be a treatment for PSP.	davunetide	73-83	microtubule associated protein tau	Homo sapiens	58-61
25484074-3	2014	The drug candidate NAP (davunetide), a peptide fragment from ADNP, enhanced the ADNP-LC3B interaction.	davunetide	24-34	activity-dependent neuroprotective protein	Mus musculus	61-65
25484074-3	2014	The drug candidate NAP (davunetide), a peptide fragment from ADNP, enhanced the ADNP-LC3B interaction.	davunetide	24-34	activity-dependent neuroprotective protein	Mus musculus	80-84
25484074-3	2014	The drug candidate NAP (davunetide), a peptide fragment from ADNP, enhanced the ADNP-LC3B interaction.	davunetide	24-34	microtubule-associated protein 1 light chain 3 beta	Mus musculus	85-89
24533805-1	2014	This review focuses on the therapeutic effects and mechanisms of action of NAP (davunetide), an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP) which was discovered in the laboratory of Prof. Illana Gozes.	davunetide	80-90	catenin beta like 1	Homo sapiens	75-78
24120997-5	2014	In this work we provide new evidence that an agent that promotes microtubule network assembly, NAP (davunetide), improves microtubule-dependent traffic, restores the autophagic flux and potentiates autophagosome-lysosome fusion leading to autophagic vacuole clearance in Parkinson"s disease cells.	davunetide	100-110	catenin beta like 1	Homo sapiens	95-98
24533805-1	2014	This review focuses on the therapeutic effects and mechanisms of action of NAP (davunetide), an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP) which was discovered in the laboratory of Prof. Illana Gozes.	davunetide	80-90	activity dependent neuroprotector homeobox	Homo sapiens	134-176
24533805-1	2014	This review focuses on the therapeutic effects and mechanisms of action of NAP (davunetide), an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP) which was discovered in the laboratory of Prof. Illana Gozes.	davunetide	80-90	activity dependent neuroprotector homeobox	Homo sapiens	178-182
23631872-0	2013	NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.	davunetide	5-15	catenin, beta like 1	Mus musculus	0-3
24210139-0	2013	Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).	davunetide	110-120	HEM-protein	Drosophila melanogaster	122-125
24210139-1	2013	This review focuses on the therapeutic effects and mechanisms of action of NAP (davunetide), an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP) which was discovered in our laboratory.	davunetide	80-90	HEM-protein	Drosophila melanogaster	75-78
24210139-4	2013	Clinical trials with NAP (davunetide) are reviewed paving the path to future developments.	davunetide	26-36	HEM-protein	Drosophila melanogaster	21-24
23631872-1	2013	NAP (davunetide) is a novel neuroprotective compound with mechanism of action that appears to involve microtubule (MT) stabilization and repair.	davunetide	5-15	catenin, beta like 1	Mus musculus	0-3
22956189-2	2012	Davunetide is an eight-amino-acid peptide fragment derived by structure-activity studies from activity-dependent neuroprotective protein, activity-dependent neuroprotective protein (ADNP).	davunetide	0-10	activity-dependent neuroprotective protein	Mus musculus	94-136
23453061-0	2013	Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration.	davunetide	77-88	lactotransferrin	Rattus norvegicus	0-11
22956189-2	2012	Davunetide is an eight-amino-acid peptide fragment derived by structure-activity studies from activity-dependent neuroprotective protein, activity-dependent neuroprotective protein (ADNP).	davunetide	0-10	activity-dependent neuroprotective protein	Mus musculus	138-180
22956189-2	2012	Davunetide is an eight-amino-acid peptide fragment derived by structure-activity studies from activity-dependent neuroprotective protein, activity-dependent neuroprotective protein (ADNP).	davunetide	0-10	activity-dependent neuroprotective protein	Mus musculus	182-186
22956189-4	2012	ADNP haploinsufficiency in mice results in tauopathy and cognitive deficits ameliorated by davunetide treatment.	davunetide	91-101	activity-dependent neuroprotective protein	Mus musculus	0-4
23272107-2	2012	NAP (NAPVSIPQ) is a neuroprotective peptide derived from the essential activity-dependent neuroprotective protein (ADNP).	davunetide	5-13	activity-dependent neuroprotector homeobox	Rattus norvegicus	71-113
23272107-2	2012	NAP (NAPVSIPQ) is a neuroprotective peptide derived from the essential activity-dependent neuroprotective protein (ADNP).	davunetide	5-13	activity-dependent neuroprotector homeobox	Rattus norvegicus	115-119
21827858-0	2011	Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model.	davunetide	0-10	catenin, beta like 1	Rattus norvegicus	12-15
21827858-2	2011	NAP (generic name, davunetide), a neuroprotective peptide was tested here for its ability to prevent diabetes-related brain pathologies in the streptozotocin injected diabetes rat model.	davunetide	19-29	catenin, beta like 1	Rattus norvegicus	0-3
20678069-6	2010	Our findings show that ADNP-deficiency leads to tauopathy which is inhibited by the ADNP derived drug candidate, davunetide (originally known as NAP).	davunetide	113-123	activity dependent neuroprotector homeobox	Homo sapiens	23-27
21453737-3	2011	In the present study, we have investigated the antioxidant and memory protection efficacy of the synthetic NAP peptide (NAPVSIPQ) during long-term chronic hypobaric hypoxia (7, 14, 21 and 28 days, 25,000ft) in rats.	davunetide	120-128	catenin, beta like 1	Rattus norvegicus	107-110
21050875-0	2011	Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate.	davunetide	79-89	catenin, beta like 1	Mus musculus	91-94
21050875-1	2011	NAP (davunetide) is an active fragment of activity-dependent neuroprotective protein (ADNP).	davunetide	5-15	catenin, beta like 1	Mus musculus	0-3
21050875-1	2011	NAP (davunetide) is an active fragment of activity-dependent neuroprotective protein (ADNP).	davunetide	5-15	activity-dependent neuroprotective protein	Mus musculus	42-84
21050875-1	2011	NAP (davunetide) is an active fragment of activity-dependent neuroprotective protein (ADNP).	davunetide	5-15	activity-dependent neuroprotective protein	Mus musculus	86-90
21524250-0	2011	NAP (davunetide) provides functional and structural neuroprotection.	davunetide	5-15	catenin beta like 1	Homo sapiens	0-3
21524250-1	2011	NAP (davunetide) is an eight amino acid peptide (NAPVSIPQ) that has been shown to provide potent neuroprotection, in vitro and in vivo.	davunetide	5-15	catenin beta like 1	Homo sapiens	0-3
21524250-1	2011	NAP (davunetide) is an eight amino acid peptide (NAPVSIPQ) that has been shown to provide potent neuroprotection, in vitro and in vivo.	davunetide	49-57	catenin beta like 1	Homo sapiens	0-3
21902667-4	2011	NAP (davunetide), an eight amino acid peptide derived from ADNP partly ameliorated deficits associated with ADNP deficiency.	davunetide	5-15	activity dependent neuroprotector homeobox	Homo sapiens	59-63
21902667-5	2011	NAP (davunetide) interacted with microtubules, protected against microtubule toxicity associated with zinc, nocodazole and oxidative stress in vitro and against tau pathology and MAP6 (stable tubuleonly polypeptide - STOP) pathology in vivo.	davunetide	5-15	microtubule associated protein 6	Homo sapiens	179-183
21902667-6	2011	NAP (davunetide) provided neurotrophic functions promoting neurite outgrowth as measured by increases in MAP2 immunoreactivity and synapse formation by increasing synaptophysin expression.	davunetide	5-15	microtubule associated protein 2	Homo sapiens	105-109
21902667-6	2011	NAP (davunetide) provided neurotrophic functions promoting neurite outgrowth as measured by increases in MAP2 immunoreactivity and synapse formation by increasing synaptophysin expression.	davunetide	5-15	synaptophysin	Homo sapiens	163-176
19923857-1	2010	BACKGROUND: Activity-dependent neuroprotector (ADNP) is a neuroprotective molecule containing an 8-amino acid peptide, NAPVSIPQ (NAP), that is sufficient for its neuroprotective effects.	davunetide	119-127	activity dependent neuroprotector homeobox	Homo sapiens	12-45
20359852-1	2010	NAP (NAPVSIPQ) is a short peptide derived from activity-dependent neuroprotective protein (ADNP) sequence, whose potent and direct neuroprotective capabilities have been widely accepted.	davunetide	5-13	activity-dependent neuroprotector homeobox	Rattus norvegicus	47-89
20359852-1	2010	NAP (NAPVSIPQ) is a short peptide derived from activity-dependent neuroprotective protein (ADNP) sequence, whose potent and direct neuroprotective capabilities have been widely accepted.	davunetide	5-13	activity-dependent neuroprotector homeobox	Rattus norvegicus	91-95
20417241-0	2010	NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.	davunetide	5-15	microtubule-associated protein 6	Mus musculus	52-56
20417241-1	2010	NAP (generic name, davunetide) is an active fragment of activity-dependent neuroprotective protein (ADNP).	davunetide	19-29	activity-dependent neuroprotective protein	Mus musculus	56-98
20417241-1	2010	NAP (generic name, davunetide) is an active fragment of activity-dependent neuroprotective protein (ADNP).	davunetide	19-29	activity-dependent neuroprotective protein	Mus musculus	100-104
19844808-3	2010	Activity-dependent neuroprotective protein (ADNP) plays an essential role in brain development, and NAP (NAPVSIPQ, generic name: davunetide)--a peptide derived from ADNP--is currently in clinical development for the treatment of neurodegenerative disorders.	davunetide	105-113	activity-dependent neuroprotective protein	Mus musculus	165-169
19844808-3	2010	Activity-dependent neuroprotective protein (ADNP) plays an essential role in brain development, and NAP (NAPVSIPQ, generic name: davunetide)--a peptide derived from ADNP--is currently in clinical development for the treatment of neurodegenerative disorders.	davunetide	129-139	activity-dependent neuroprotective protein	Mus musculus	165-169
19619522-1	2009	NAPVSIPQ (NAP), an 8 amino acid peptide derived from activity-dependent neuroprotective protein (ADNP), provides neuroprotection through interaction with microtubules.	davunetide	0-8	activity-dependent neuroprotector homeobox	Rattus norvegicus	53-95
19619522-1	2009	NAPVSIPQ (NAP), an 8 amino acid peptide derived from activity-dependent neuroprotective protein (ADNP), provides neuroprotection through interaction with microtubules.	davunetide	0-8	activity-dependent neuroprotector homeobox	Rattus norvegicus	97-101
19327737-2	2009	Prenatal NAPVSIPQ (NAP) and SALLRSIPA (SAL) (NAP+SAL) prevent developmental delay in Ts65Dn mice, a mouse model of DS.	davunetide	9-17	reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65	Mus musculus	85-91
19091000-1	2008	INTRODUCTION: NAP (Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln, single amino acid letter code, NAPVSIPQ), an eight amino acid neuroprotective peptide derived from activity-dependent neuroprotective protein (ADNP), exhibits some structural similarity to activity-dependent neurotropic factor-9 (ADNF-9; Ser-Alal-Leu-Leu-Arg-Ser-Ile-Pro-Ala, SALLRSIPA).	davunetide	19-50	activity-dependent neuroprotector homeobox	Rattus norvegicus	151-193
19073235-3	2009	This peptide with the sequence NAPVSIPQ, known as NAP, a fragment of activity-dependent neuroprotective protein, demonstrated a potent protective effect against oxidative stress associated with alcohol exposure.	davunetide	31-39	activity-dependent neuroprotective protein	Mus musculus	69-111
19047645-3	2008	NAPVSIPQ (NAP), a potent active fragment of ADNP, potentiated axon outgrowth in cerebellar granule neurons by activating the sequential tyrosine phosphorylation of Fyn kinase and the scaffold protein Crk-associated substrate (Cas).	davunetide	0-8	activity dependent neuroprotector homeobox	Homo sapiens	44-48
19047645-3	2008	NAPVSIPQ (NAP), a potent active fragment of ADNP, potentiated axon outgrowth in cerebellar granule neurons by activating the sequential tyrosine phosphorylation of Fyn kinase and the scaffold protein Crk-associated substrate (Cas).	davunetide	0-8	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	164-167
19047645-3	2008	NAPVSIPQ (NAP), a potent active fragment of ADNP, potentiated axon outgrowth in cerebellar granule neurons by activating the sequential tyrosine phosphorylation of Fyn kinase and the scaffold protein Crk-associated substrate (Cas).	davunetide	0-8	BCAR1 scaffold protein, Cas family member	Homo sapiens	200-224
19047645-3	2008	NAPVSIPQ (NAP), a potent active fragment of ADNP, potentiated axon outgrowth in cerebellar granule neurons by activating the sequential tyrosine phosphorylation of Fyn kinase and the scaffold protein Crk-associated substrate (Cas).	davunetide	0-8	BCAR1 scaffold protein, Cas family member	Homo sapiens	226-229
17869381-1	2007	The femtomolar-acting protective peptide NAP (NAPVSIPQ), derived from activity-dependent neuroprotective protein (ADNP), is broadly neuroprotective in vivo and in vitro in cerebral cortical cultures and a variety of cell lines.	davunetide	46-54	activity dependent neuroprotector homeobox	Homo sapiens	70-112
18600585-0	2008	AL-108 and AL-208, formulations of the neuroprotective NAP fragment of activity-dependent neuroprotective protein, for cognitive disorders.	davunetide	0-6	catenin beta like 1	Homo sapiens	55-58
18600585-0	2008	AL-108 and AL-208, formulations of the neuroprotective NAP fragment of activity-dependent neuroprotective protein, for cognitive disorders.	davunetide	11-17	catenin beta like 1	Homo sapiens	55-58
18600585-1	2008	Allon Therapeutics Inc is developing AL-108, an intranasally administered, eight-amino-acid peptide fragment (known as NAP) of activity-dependent neuroprotective protein, and AL-208, an intravenous formulation of NAP.	davunetide	37-43	catenin beta like 1	Homo sapiens	119-122
17720885-7	2007	NAP (NAPVSIPQ) is a peptide derived from ADNP that interacts with microtubules and provides potent neuroprotection.	davunetide	5-13	activity-dependent neuroprotective protein	Mus musculus	41-45
18414890-1	2008	BACKGROUND: NAP, an 8-amino acid peptide (NAPVSIPQ=Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln) derived from activity-dependent neuroprotective protein (ADNP), plays an important role in neuronal differentiation and the survival of neurons in different pathological situations.	davunetide	42-50	catenin, beta like 1	Rattus norvegicus	12-15
18414890-1	2008	BACKGROUND: NAP, an 8-amino acid peptide (NAPVSIPQ=Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln) derived from activity-dependent neuroprotective protein (ADNP), plays an important role in neuronal differentiation and the survival of neurons in different pathological situations.	davunetide	42-50	activity-dependent neuroprotector homeobox	Rattus norvegicus	97-139
18414890-1	2008	BACKGROUND: NAP, an 8-amino acid peptide (NAPVSIPQ=Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln) derived from activity-dependent neuroprotective protein (ADNP), plays an important role in neuronal differentiation and the survival of neurons in different pathological situations.	davunetide	42-50	activity-dependent neuroprotector homeobox	Rattus norvegicus	141-145
18414890-1	2008	BACKGROUND: NAP, an 8-amino acid peptide (NAPVSIPQ=Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln) derived from activity-dependent neuroprotective protein (ADNP), plays an important role in neuronal differentiation and the survival of neurons in different pathological situations.	davunetide	51-82	catenin, beta like 1	Rattus norvegicus	12-15
18414890-1	2008	BACKGROUND: NAP, an 8-amino acid peptide (NAPVSIPQ=Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln) derived from activity-dependent neuroprotective protein (ADNP), plays an important role in neuronal differentiation and the survival of neurons in different pathological situations.	davunetide	51-82	activity-dependent neuroprotector homeobox	Rattus norvegicus	97-139
18414890-1	2008	BACKGROUND: NAP, an 8-amino acid peptide (NAPVSIPQ=Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln) derived from activity-dependent neuroprotective protein (ADNP), plays an important role in neuronal differentiation and the survival of neurons in different pathological situations.	davunetide	51-82	activity-dependent neuroprotector homeobox	Rattus norvegicus	141-145
18220512-1	2007	NAP (NAPVSIPQ), derived from activity-dependent neuroprotective protein (ADNP) provides neuroprotection in vitro and in vivo against a wide variety of neurotoxic substances.	davunetide	5-13	activity dependent neuroprotector homeobox	Homo sapiens	29-71
18220512-1	2007	NAP (NAPVSIPQ), derived from activity-dependent neuroprotective protein (ADNP) provides neuroprotection in vitro and in vivo against a wide variety of neurotoxic substances.	davunetide	5-13	activity dependent neuroprotector homeobox	Homo sapiens	73-77
17869381-1	2007	The femtomolar-acting protective peptide NAP (NAPVSIPQ), derived from activity-dependent neuroprotective protein (ADNP), is broadly neuroprotective in vivo and in vitro in cerebral cortical cultures and a variety of cell lines.	davunetide	46-54	activity dependent neuroprotector homeobox	Homo sapiens	114-118
17363064-7	2007	In this respect, structure-activity studies have identified a short 8 amino acid peptide in ADNP/NAPVSIPQ (NAP) that provides potent neuroprotection.	davunetide	97-105	activity dependent neuroprotector homeobox	Homo sapiens	92-96
16488478-11	2006	The peptide derivatives of ADNF, ADNF-14 (VLGGGSALLRSIPA), ADNF-9 (or SALLRSIPA = SAL) and of ADNP, NAPVSIPQ = NAP have shown neuroprotective effects and have been proven to prevent brain damage associated with prenatal alcohol exposure in animals.	davunetide	100-108	activity dependent neuroprotector homeobox	Homo sapiens	94-98
15135910-1	2004	NAP, an 8-amino-acid peptide (NAPVSIPQ=Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln), provides neuroprotection at very low doses in a variety of animal models.	davunetide	39-70	catenin, beta like 1	Mus musculus	0-3
16888216-1	2006	NAP is an eight-amino acid neuroprotective peptide NAPVSIPQ; it is the smallest active element derived from the recently cloned activity-dependent neuroprotective protein (ADNP).	davunetide	51-59	catenin beta like 1	Homo sapiens	0-3
16888216-1	2006	NAP is an eight-amino acid neuroprotective peptide NAPVSIPQ; it is the smallest active element derived from the recently cloned activity-dependent neuroprotective protein (ADNP).	davunetide	51-59	activity dependent neuroprotector homeobox	Homo sapiens	128-170
16888216-1	2006	NAP is an eight-amino acid neuroprotective peptide NAPVSIPQ; it is the smallest active element derived from the recently cloned activity-dependent neuroprotective protein (ADNP).	davunetide	51-59	activity dependent neuroprotector homeobox	Homo sapiens	172-176
15974912-1	2005	NAP is a short octapeptide sequence (single letter code, NAPVSIPQ) that protects neurons against a wide variety of insults.	davunetide	57-65	catenin, beta like 1	Mus musculus	0-3
15135910-1	2004	NAP, an 8-amino-acid peptide (NAPVSIPQ=Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln), provides neuroprotection at very low doses in a variety of animal models.	davunetide	30-38	catenin, beta like 1	Mus musculus	0-3
11193814-2	2000	Activity dependent neuroprotective protein (ADNP, 828 amino acids, pI 5.99) is a glial-derived protein that contains a femtomolar active neuroprotective peptide, NAPVSIPQ (NAP).	davunetide	162-170	activity-dependent neuroprotective protein	Mus musculus	0-42
15314252-1	2004	An 8-amino-acid peptide, NAPVSIPQ (NAP), was identified as the smallest active element of activity-dependent neuroprotective protein that exhibits potent neuroprotective action.	davunetide	25-33	activity dependent neuroprotector homeobox	Homo sapiens	90-132
12220738-2	2002	Previous work has demonstrated that peptide agonists (SALLRSIPA and NAPVSIPQ) from downstream mediators that are regulated by VIP were able to prevent the alcohol-induced fetal death, growth restriction and microcephaly associated with fetal alcohol syndrome.	davunetide	68-76	vasoactive intestinal polypeptide	Mus musculus	126-129
11102650-1	2000	We have recently cloned a novel protein (activity-dependent neuroprotective protein, ADNP) containing an 8-amino-acid, femtomolar-acting peptide, NAPVSIPQ (NAP).	davunetide	146-154	activity-dependent neuroprotector homeobox	Rattus norvegicus	41-83
11102650-1	2000	We have recently cloned a novel protein (activity-dependent neuroprotective protein, ADNP) containing an 8-amino-acid, femtomolar-acting peptide, NAPVSIPQ (NAP).	davunetide	146-154	activity-dependent neuroprotector homeobox	Rattus norvegicus	85-89
11193814-2	2000	Activity dependent neuroprotective protein (ADNP, 828 amino acids, pI 5.99) is a glial-derived protein that contains a femtomolar active neuroprotective peptide, NAPVSIPQ (NAP).	davunetide	162-170	activity-dependent neuroprotective protein	Mus musculus	44-48
34865853-4	2021	Phenotypic rescue was validated by treatment with the microtubule/autophagy-protective ADNP fragment NAPVSIPQ (NAP).	davunetide	101-109	activity-dependent neuroprotective protein	Mus musculus	87-91